SCHEMBL2122331

SCHEMBL2122331

N#Cc1cccc(Nc2c(-c3ccccn3)nc3c(C#N)c[nH]n23)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 2/20 0.47
▸ TP53 P04637 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ GAA P10253 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ HTT P42858 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ KDM5A P29375 4/20 0.40
▸ GRM4 Q14833 1/20 0.39
▸ GRM5 P41594 3/20 0.39
▸ PTGS2 P35354 1/20 0.39
▸ MITF O75030 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ CDK4 P11802 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CSNK2A2 P19784 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2132433 0.87 MAPT (0.41) ABCG2TP53MAPTGAASMN1; SMN2
SCHEMBL2125958 0.87 KDM5A (0.48) TP53MAPTGAASMN1; SMN2HTT
SCHEMBL2125082 0.86 MAPT (0.43) ABCG2TP53MAPTSMN1; SMN2KDM5A
SCHEMBL2123837 0.84 MAPT (0.52) TP53MAPTKDM5A
SCHEMBL2876451 0.82 MAPT (0.54) TP53MAPTGAASMN1; SMN2HTT
SCHEMBL2122035 0.81 KDM5A (0.54) ABCG2TP53MAPTGAASMN1; SMN2
SCHEMBL2124185 0.81 KDM5A (0.50) TP53MAPTKDM5A
SCHEMBL2123003 0.81 KDM5A (0.46) TP53MAPTGAAHTTLMNA
SCHEMBL2123600 0.81 KDM5A (0.41) TP53MAPTGAAHTTLMNA
SCHEMBL2124994 0.79 MAPT (0.48) TP53MAPTGAAKDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK ABCG2 2365/4885TP53 639/4885MAPT 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback